These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 31362741)

  • 41. Biomarkers for severe eosinophilic asthma.
    Yancey SW; Keene ON; Albers FC; Ortega H; Bates S; Bleecker ER; Pavord I
    J Allergy Clin Immunol; 2017 Dec; 140(6):1509-1518. PubMed ID: 29221581
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Proportion of Severe Asthma Patients Eligible for Mepolizumab Therapy by Age and Age of Onset of Asthma.
    Comberiati P; McCormack K; Malka-Rais J; Spahn JD
    J Allergy Clin Immunol Pract; 2019; 7(8):2689-2696.e2. PubMed ID: 31201938
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cluster analysis and characterization of response to mepolizumab. A step closer to personalized medicine for patients with severe asthma.
    Ortega H; Li H; Suruki R; Albers F; Gordon D; Yancey S
    Ann Am Thorac Soc; 2014 Sep; 11(7):1011-7. PubMed ID: 24983709
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Mepolizumab for eosinophilic severe asthma: recent studies.
    Robinson DS; Kariyawasam HH
    Expert Opin Biol Ther; 2015 Jun; 15(6):909-14. PubMed ID: 25951938
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Mepolizumab add-on therapy in a real world cohort of patients with severe eosinophilic asthma: response rate, effectiveness, and safety.
    van Toor JJ; van der Mark SC; Kappen JH; In 't Veen JCCM; Braunstahl GJ
    J Asthma; 2021 May; 58(5):651-658. PubMed ID: 31999203
    [No Abstract]   [Full Text] [Related]  

  • 46. Mepolizumab for the treatment of severe eosinophilic asthma.
    Poulakos MN; Cargill SM; Waineo MF; Wolford AL
    Am J Health Syst Pharm; 2017 Jul; 74(13):963-969. PubMed ID: 28645995
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy of mepolizumab for patients with severe asthma and eosinophilic chronic rhinosinusitis.
    Numata T; Nakayama K; Utsumi H; Kobayashi K; Yanagisawa H; Hashimoto M; Minagawa S; Ishikawa T; Hara H; Araya J; Kuwano K
    BMC Pulm Med; 2019 Oct; 19(1):176. PubMed ID: 31606052
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Mepolizumab effectiveness and identification of super-responders in severe asthma.
    Harvey ES; Langton D; Katelaris C; Stevens S; Farah CS; Gillman A; Harrington J; Hew M; Kritikos V; Radhakrishna N; Bardin P; Peters M; Reynolds PN; Upham JW; Baraket M; Bowler S; Bowden J; Chien J; Chung LP; Grainge C; Jenkins C; Katsoulotos GP; Lee J; McDonald VM; Reddel HK; Rimmer J; Wark PAB; Gibson PG
    Eur Respir J; 2020 May; 55(5):. PubMed ID: 32139455
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Stopping
    Moore WC; Kornmann O; Humbert M; Poirier C; Bel EH; Kaneko N; Smith SG; Martin N; Gilson MJ; Price RG; Bradford ES; Liu MC
    Eur Respir J; 2022 Jan; 59(1):. PubMed ID: 34172470
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma.
    Bel EH; Wenzel SE; Thompson PJ; Prazma CM; Keene ON; Yancey SW; Ortega HG; Pavord ID;
    N Engl J Med; 2014 Sep; 371(13):1189-97. PubMed ID: 25199060
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Switching Treatment from Mepolizumab to Benralizumab for Elderly Patients with Severe Eosinophilic Asthma: A Retrospective Observational Study.
    Isoyama S; Ishikawa N; Hamai K; Matsumura M; Kobayashi H; Nomura A; Ueno S; Tanimoto T; Maeda H; Iwamoto H; Hattori N
    Intern Med; 2022; 61(11):1663-1671. PubMed ID: 35650114
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Mepolizumab and exacerbations of refractory eosinophilic asthma.
    Haldar P; Brightling CE; Hargadon B; Gupta S; Monteiro W; Sousa A; Marshall RP; Bradding P; Green RH; Wardlaw AJ; Pavord ID
    N Engl J Med; 2009 Mar; 360(10):973-84. PubMed ID: 19264686
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Mepolizumab for urban children with exacerbation-prone eosinophilic asthma in the USA (MUPPITS-2): a randomised, double-blind, placebo-controlled, parallel-group trial.
    Jackson DJ; Bacharier LB; Gergen PJ; Gagalis L; Calatroni A; Wellford S; Gill MA; Stokes J; Liu AH; Gruchalla RS; Cohen RT; Makhija M; Khurana Hershey GK; O'Connor GT; Pongracic JA; Sherenian MG; Rivera-Spoljaric K; Zoratti EM; Teach SJ; Kattan M; Dutmer CM; Kim H; Lamm C; Sheehan WJ; Segnitz RM; Dill-McFarland KA; Visness CM; Becker PM; Gern JE; Sorkness CA; Busse WW; Altman MC;
    Lancet; 2022 Aug; 400(10351):502-511. PubMed ID: 35964610
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma.
    Khatri S; Moore W; Gibson PG; Leigh R; Bourdin A; Maspero J; Barros M; Buhl R; Howarth P; Albers FC; Bradford ES; Gilson M; Price RG; Yancey SW; Ortega H
    J Allergy Clin Immunol; 2019 May; 143(5):1742-1751.e7. PubMed ID: 30359681
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Asthma Exacerbations Associated with Lung Function Decline in Patients with Severe Eosinophilic Asthma.
    Ortega H; Yancey SW; Keene ON; Gunsoy NB; Albers FC; Howarth PH
    J Allergy Clin Immunol Pract; 2018; 6(3):980-986.e1. PubMed ID: 29398640
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Association of depressive symptoms with health status and markers of uncontrolled severe asthma.
    Khurana S; Lyness JM; Mallett S; Nelsen LM; Prazma CM; Albers FC; Forshag M; Llanos JP; Yancey SW; Ortega HG
    Allergy Asthma Proc; 2019 Jul; 40(4):230-239. PubMed ID: 31262378
    [No Abstract]   [Full Text] [Related]  

  • 57. REal worlD Effectiveness and Safety of Mepolizumab in a Multicentric Spanish Cohort of Asthma Patients Stratified by Eosinophils: The REDES Study.
    Domingo Ribas C; Carrillo Díaz T; Blanco Aparicio M; Martínez Moragón E; Banas Conejero D; Sánchez Herrero MG;
    Drugs; 2021 Oct; 81(15):1763-1774. PubMed ID: 34586602
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Mepolizumab improves small airway function in severe eosinophilic asthma.
    Farah CS; Badal T; Reed N; Rogers PG; King GG; Thamrin C; Peters MJ; Seccombe LM
    Respir Med; 2019 Mar; 148():49-53. PubMed ID: 30827474
    [TBL] [Abstract][Full Text] [Related]  

  • 59. No genetic association detected with mepolizumab efficacy in severe asthma.
    Condreay L; Chiano M; Ortega H; Buchan N; Harris E; Bleecker ER; Thompson PJ; Humbert M; Gibson P; Yancey S; Ghosh S
    Respir Med; 2017 Nov; 132():178-180. PubMed ID: 29229094
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A Comprehensive Evaluation of Mepolizumab Effectiveness in a Real-Life Setting.
    Cameli P; Bergantini L; d'Alessandro M; Perruzza M; Cekorja B; Perillo F; Massa E; Ruzza A; Fossi A; Beltrami V; Sestini P; Bargagli E
    Int Arch Allergy Immunol; 2020; 181(8):606-612. PubMed ID: 32516771
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.